Logo Image
Opinion|Videos|June 2, 2025

Equitable Access to Molecular Testing and Treatment Prioritization

Panelists discuss how to overcome barriers to comprehensive molecular testing and how to prioritize treatment when ALK+ non–small cell lung cancer (NSCLC) coexists with other actionable biomarkers.

Episodes in this series

Molecular Testing and Biomarker Considerations

Key Themes:

  • Barriers to equitable access for comprehensive molecular testing
  • Strategies to overcome testing barriers
  • Treatment prioritization when ALK+ status coexists with other actionable biomarkers

Notable Insights:

  • Dr Dietrich identified barriers to comprehensive molecular testing including NGS
  • Grizzard offered suggestions for clinicians to overcome testing barriers

Dr Lovly addressed treatment prioritization in patients with both ALK+ status and other biomarkers (eg, PD-L1 >1%)

Related Content